TICKERNERD
Menu
KROSKROSHealthcare · Biotechnology

KROS Stock Forecast: Keros Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$11
−0.81% on the day

The 7 Wall Street analysts covering Keros Therapeutics, Inc. hold a median 12-month price target of $19 — +71.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 12 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$219.7M
Ticker Nerd rank
71 / 100
Median analyst target
$19
Analysts covering
7
Revenue$0.0−100.0% y/y
Operating income−$30.9M
Net income−$28.7M
Free cash flow−$20.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.3%
1M
+4.1%
YTD
−45.6%
1Y
−29.7%
From 52W high
−49.3%
From 52W low
+11.8%
$10
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KROS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Keros Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
71 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
96
Quality
88
Accruals
81
Volatility
72
Revisions
71
Size
67
Momentum
32
Value
22
Growth
9

Issuance (96): The share count has been shrinking and the company is not leaning on new borrowing.

Growth (9): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KROS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KROS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25Oct 25Jan 26Apr 26Jul 26KROSHigh $25Median $19Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
4 Buy3 Hold0 Sell
Low $16Median $19High $25

The green dot is the last close — the median target sits +71.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
4 Aug 2026Leerink PartnersMaintainsOutperform$30 → $23
4 Aug 2026Wells FargoMaintainsOverweight$20 → $18
5 Mar 2026Wells FargoMaintainsOverweight$23 → $20
5 Mar 2026Wells FargoMaintainsOverweight—
28 Nov 2025B of A SecuritiesMaintainsNeutral—
12 Nov 2025OppenheimerReiteratesOutperform—
11 Nov 2025Wells FargoMaintainsOverweight—
6 Nov 2025WedbushMaintainsNeutral—
8 Aug 2025HC Wainwright & Co.MaintainsBuy—
10 June 2025B of A SecuritiesDowngradeNeutral—
30 May 2025WedbushReiteratesNeutral—
12 May 2025ScotiabankMaintainsSector Outperform—
8 May 2025HC Wainwright & Co.MaintainsBuy—
9 Apr 2025Truist SecuritiesMaintainsBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
1 Apr 2025WedbushReiteratesNeutral—
27 Feb 2025HC Wainwright & Co.MaintainsBuy—
27 Feb 2025Wells FargoMaintainsOverweight—
21 Jan 2025Cantor FitzgeraldDowngradeNeutral—
17 Jan 2025GuggenheimReiteratesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KROS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KROS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Keros Therapeutics, Inc. returned −29.7% against +17.5% for the S&P 500, dividends included.

KROS vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Oct 25Jan 26Apr 26Jul 26KROSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KROS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
2
Fundamentals

Keros Therapeutics, Inc. (KROS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
4.6×

Cheaper than 66% of US stocks

Price / sales
14.6×

Cheaper than 11% of US stocks

Price / book
0.8×

Cheaper than 78% of US stocks

EV / EBITDA
0.2×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−655.8%

Higher than 7% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−17.2%

Higher than 32% of US stocks

Return on assets
−11.8%

Higher than 25% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Keros Therapeutics, Inc. (KROS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Keros Therapeutics, Inc. has a market value of $219.7M and an enterprise value of −$22.2M.

  • Revenue in the twelve months to 30 June 2026: $15.0M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$83.2M, a −553.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.70.

  • Free cash flow in the twelve months to 30 June 2026: −$48.5M.

  • Shares outstanding: 19.8M.

  • Trailing P/E: 4.6×; forward P/E: −1.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Keros Therapeutics, Inc. employs 92 people — $163K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

KROS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KROSKeros Therapeutics, Inc.$219.7M
71
SRZNSurrozen, Inc.$218.2M
72
SLGLSol-Gel Technologies Ltd.$215.6M
42
PLXProtalix Biotherapeutics, Inc.$212.7M
89
TARAProtara Therapeutics, Inc.$225.7M
37
ELDNEledon Pharmaceuticals, Inc.$225.9M
36
ABOSAcumen Pharmaceuticals, Inc.$210.9M
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Keros Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KROS news & analysis

Keros Therapeutics Announces $5 Million Share Repurchase Authorization

GlobeNewsWire · 8 Sept 2026positive

Keros Therapeutics announced that its Board of Directors approved a $5 million share repurchase program for the company's common stock, authorizing management to repurchase shares from time to time in the open market or by other means in accordance with securities laws. The authorization follows receipt of a $20 million development milestone payment under the elritercept license agreement with Takeda Pharmaceuticals, triggered by the dosing of the first patient in the ELRiSE MDS clinical trial.

Why it matters — A KROS watcher would care because the repurchase program signals the company has unlocked milestone revenue from its Takeda partnership and is returning capital to shareholders.

Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?

Zacks Investment Research · 2 Sept 2026positive

Keros Therapeutics (KROS) reported earnings about 30 days ago, and the stock has risen 8% since that report. The item examines what may come next for the company's shares.

Why it matters — KROS watchers would care because the post-earnings price gain signals investor interest and raises the question of whether the momentum will continue going forward.

Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?

Zacks Investment Research · 24 Aug 2026negative

Zacks Investment Research published a cautious assessment of Keros Therapeutics, noting that its rinvatercept pipeline offers upside potential while the company faces zero quarterly revenue, clinical risk, and a premium valuation, making the stock a cautious bet.

Why it matters — KROS watchers would care because the item weighs the promise of the rinvatercept pipeline against the financial and clinical risks currently facing the company.

KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

Zacks Investment Research · 24 Aug 2026negative

Keros Therapeutics received a $20 million milestone payment from Takeda, which adds cash and increases financial flexibility. However, weak revenue visibility continues to keep collaboration income as the main focus.

Why it matters — KROS watchers would care because the milestone strengthens the balance sheet while persistent weak revenue visibility keeps uncertainty around future collaboration income.

KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus

Zacks Investment Research · 4 Aug 2026neutral

Keros Therapeutics reported a wider second-quarter loss as revenues fell to zero, missing earnings expectations. The company's cash runway extends into H1 2028, with rinvatercept pipeline milestones keeping attention on future growth.

Why it matters — A KROS watcher would care because the company's cash position and rinvatercept pipeline progress are central to how the company can fund and deliver future growth after quarterly revenue fell to zero.

FAQ

Frequently asked questions about KROS stock

What is the KROS stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Keros Therapeutics, Inc. have a median 12-month price target of $19, with estimates ranging from $16 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KROS stock a buy right now?

Of the 7 analysts covering Keros Therapeutics, Inc., 4 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Keros Therapeutics, Inc. 71 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KROS?

As at 12 Sept 2026, Keros Therapeutics, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (96 of 100).

Will KROS stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +71.5% from the last close, and Ticker Nerd's factor model ranks Keros Therapeutics, Inc. 71 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KROS stock forecast for 2030?

No analyst covering Keros Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KROS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $25 over the next 12 months.

How has KROS stock performed over the past year?

Keros Therapeutics, Inc. returned -29.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Keros Therapeutics, Inc. do?

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for disorders linked to dysfunctional signaling in the transforming growth factor-beta family of proteins.

What is the latest news on KROS?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "Keros Therapeutics Announces $5 Million Share Repurchase Authorization". Keros Therapeutics announced that its Board of Directors approved a $5 million share repurchase program for the company's common stock, authorizing management to repurchase shares from time to time in the open market or by other means in accordance with securities laws. The authorization follows receipt of a $20 million development milestone payment under the elritercept license agreement with Takeda Pharmaceuticals, triggered by the dosing of the first patient in the ELRiSE MDS clinical trial.

Company

About Keros Therapeutics, Inc.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for disorders linked to dysfunctional signaling in the transforming growth factor-beta family of proteins. Its current pipeline centers on candidates designed to address serious hematologic, pulmonary, cardiovascular, and musculoskeletal conditions, with research programs aimed at low blood cell counts, anemia, pulmonary arterial hypertension, bone-related disorders, and muscle-related diseases. The company’s work is built around protein- and pathway-based approaches that target disease mechanisms involved in red blood cell and platelet production, iron regulation, and tissue repair. Keros Therapeutics serves the biotechnology and specialty medicine markets, where it contributes to the development of precision therapies for patients with high unmet medical needs.

CEO Dr. Jasbir S. Seehra Ph.D. · 92 employees · United States · https://www.kerostx.com